Literature DB >> 8845716

Neuropathies associated with monoclonal gammopathies.

J T Kissel1, J R Mendell.   

Abstract

Approximately 10% of patients with idiopathic peripheral neuropathy have an associated serum monoclonal gammopathy or M-protein. This represents six times the incidence of M-proteins found in the general population. In 5% of idiopathic peripheral neuropathy patients the M-protein is associated with an identifiable plasma cell dyscrasia. Sclerotic myeloma is particularly important to recognize because treatment may result in amelioration of the neuropathy and remission of the tumor. Patients with primary systemic amyloidosis often have preferential small fiber involvement with a dissociated sensory loss and autonomic dysfunction. The nerve root infiltration of lymphoproliferative disorders may simulate a polyradiculoneuropathy. In cases without an identifiable cause for the M-protein, referred to as monoclonal gammopathy of undetermined significance (MGUS), the pathophysiologic basis for the neuropathy is poorly defined in most cases. A role for M-proteins with antibody activity to myelin-associated glycoprotein is provocative. This review summarizes current knowledge of this important group of disorders.

Entities:  

Mesh:

Year:  1996        PMID: 8845716     DOI: 10.1016/0960-8966(95)00021-6

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  7 in total

Review 1.  Current concepts and controversy in chronic inflammatory demyelinating polyneuropathy.

Authors:  David S Saperstein; Richard J Barohn
Journal:  Curr Neurol Neurosci Rep       Date:  2003-01       Impact factor: 5.081

2.  Axonal neuropathy associated with monoclonal gammopathy of undetermined significance.

Authors:  K C Gorson; A H Ropper
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-08       Impact factor: 10.154

3.  Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients.

Authors:  John P Bida; Robert A Kyle; Terry M Therneau; L Joseph Melton; Matthew F Plevak; Dirk R Larson; Angela Dispenzieri; Jerry A Katzmann; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2009-08       Impact factor: 7.616

Review 4.  Multifocal motor neuropathy, multifocal acquired demyelinating sensory and motor neuropathy, and other chronic acquired demyelinating polyneuropathy variants.

Authors:  Mazen M Dimachkie; Richard J Barohn; Jonathan Katz
Journal:  Neurol Clin       Date:  2013-02-16       Impact factor: 3.806

Review 5.  Cryptogenic sensory polyneuropathy.

Authors:  Mamatha Pasnoor; Mazen M Dimachkie; Richard J Barohn
Journal:  Neurol Clin       Date:  2013-03-13       Impact factor: 3.806

6.  Paraproteinemic Neuropathy.

Authors:  Matthew P. Wicklund; John T. Kissel
Journal:  Curr Treat Options Neurol       Date:  2001-03       Impact factor: 3.972

7.  Comparison of monoclonal gammopathy of undetermined significance-associated neuropathy and chronic inflammatory demyelinating polyneuropathy patients.

Authors:  Nuha M Alkhawajah; Samantha K Dunnigan; Vera Bril
Journal:  J Neurol       Date:  2014-05-07       Impact factor: 4.849

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.